1174568-18-3

Upstream product

• 3958-60-9 2-nitrophenylmethyl bromide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 179686-64-7 methyl N-(2-nitrobenzyl)glycinate 

Downstream Products

• 179686-65-8 methyl N-(2-aminobenzyl)-N-(tert-butoxycarbonyl)glycinate 
• 179686-66-9 tert-butyl 2-oxo-1,2,3,5-tetrahydro-4H-1,4-benzodiazepine-4-carboxylate 
• 1824-72-2 1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one 

Relevant academic research and scientific papers

HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and may be useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

NOVEL HETEROCYCLIC COMPOUNDS

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relat

Substituted indolines which inhibit receptor tyrosine kinases

Indolinones of the formula having an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumor cells. Exemplary are: (a) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone, and (c) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-metboxycarbonyl-2-indolinone.